Literature DB >> 18043553

From colonic polyps to colon cancer: pathophysiology, clinical presentation, screening and colonoscopic therapy.

M S Cappell1.   

Abstract

UNLABELLED: Colon cancer is the most common nondermatologic cancer in Italy and throughout Europe, with about 250,000 cases annually in Europe, about half of whom die. Yet, colon cancer is largely preventable through intensive, mass screening programs to remove premalignant colonic polyps. The persistently high incidence and mortality is largely due to ineffective implementation of established screening protocols due to patient fears about screening tests, physician under-referral for screening, and test costs. Colon cancer mostly arises from adenomas, recognized as colonic polyps, but may occasionally arise from the sessile serrated adenoma. Adenomatous polyposis coli (APC) gene mutation is the key molecular step in adenoma formation. Mismatch repair gene mutation is a less common alternative pathway. Progression from adenomas to colon cancer is a multistep process, involving mutations of the DCC, k-ras, and p53 genes; loss of heterozygosity in which cells loose one allele of some genes from chromosomal loss; and DNA methylation which can silence DNA expression. Numerous environmental factors can increase the risk of colon cancer, presumably by modulating these molecular pathways. While colon cancer in an advanced and incurable stage often produces clinical findings, premalignant adenomatous polyps and early, highly curable, colon cancer are often asymptomatic. This phenomenon renders adenomas or early cancers difficult to detect by clinical presentation and provides the rationale for mass screening of asymptomatic adults over 50 years old for early detection and prevention of colon cancer. Colonoscopy is the primary screening test. All polyps identified at colonoscopy are removed by colonoscopic polypectomy. Endoscopic mucosal resection is required for deeply penetrating noncancerous polyps. Colonoscopy is repeated every ten years if the index colonoscopy revealed no lesions, but is repeated more frequently if adenomatous polyps were identified at this colonoscopy due to an increased risk of subsequent polyps or colon cancer. Flexible sigmoidoscopy every few years with annual fecal occult blood testing is a significantly less sensitive screening protocol. Virtual colonoscopy is controversial as a screening test due to widely variable reported
RESULTS: Computerized tomography is standardly used to preoperatively detect distant colon cancer metastases, while endosonography is being increasingly used for locoregional staging of rectal cancer. Stool genetic markers and videocapsule endoscopy are promising, but currently experimental, screening tests.

Entities:  

Mesh:

Year:  2007        PMID: 18043553

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  10 in total

1.  Natural products and colon cancer: current status and future prospects.

Authors:  Subapriya Rajamanickam; Rajesh Agarwal
Journal:  Drug Dev Res       Date:  2008-11-01       Impact factor: 4.360

Review 2.  Serum tests for colorectal cancer screening.

Authors:  James Creeden; Frank Junker; Sabine Vogel-Ziebolz; Douglas Rex
Journal:  Mol Diagn Ther       Date:  2011-06-01       Impact factor: 4.074

3.  MicroRNA-4463 facilitates the development of colon cancer by suppression of the expression of PPP1R12B.

Authors:  J Tan; T Lu; J Xu; Y Hou; Z Chen; K Zhou; Y Ding; B Jiang; Y Zhu
Journal:  Clin Transl Oncol       Date:  2022-01-22       Impact factor: 3.405

4.  Endoscopic resection and histological evaluation of colorectal polyps: Is it a definitive treatment?

Authors:  Christos D Zois; Dimitrios K Christodoulou; Konstantinos H Katsanos; Dimitrios Sigounas; Anna Batistatou; Vasiliki Hatzi; Norman Marcon; Epameinondas V Tsianos
Journal:  Ann Gastroenterol       Date:  2011

5.  Detection of human papillomavirus infection by molecular tests and its relation to colonic polyps and colorectal cancer.

Authors:  Faten Gazzaz; Mahmoud H Mosli; Hani Jawa; Abdulrahman Sibiany
Journal:  Saudi Med J       Date:  2016-03       Impact factor: 1.484

6.  Quercetin Confers Tumoricidal Activity Through Multipathway Mechanisms in A N-Methylnitrosourea Rat Model of Colon Cancer

Authors:  Hanaa H Ahmed; Hadeer A Aglan; Asmaa M Zaazaa; Aziza B Shalby; Sayed A El Toumy
Journal:  Asian Pac J Cancer Prev       Date:  2016-11-01

7.  Simultaneous Assessment of the Efficacy and Toxicity of Marine Mollusc-Derived Brominated Indoles in an In Vivo Model for Early Stage Colon Cancer.

Authors:  Babak Esmaeelian; Kirsten Benkendorff; Richard K Le Leu; Catherine A Abbott
Journal:  Integr Cancer Ther       Date:  2017-04-05       Impact factor: 3.279

8.  Predictive Values of the Selected Inflammatory Indexes in Colon Cancer.

Authors:  Li Huang; Zuojian Hu; Ruixian Luo; Hailan Li; Ziji Yang; Xue Qin; Zhuning Mo
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

9.  Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions.

Authors:  Itzhak Avital; Russell C Langan; Thomas A Summers; Scott R Steele; Scott A Waldman; Vadim Backman; Judy Yee; Aviram Nissan; Patrick Young; Craig Womeldorph; Paul Mancusco; Renee Mueller; Khristian Noto; Warren Grundfest; Anton J Bilchik; Mladjan Protic; Martin Daumer; John Eberhardt; Yan Gao Man; Björn Ldm Brücher; Alexander Stojadinovic
Journal:  J Cancer       Date:  2013-03-01       Impact factor: 4.207

10.  Preventive inositol hexaphosphate extracted from rice bran inhibits colorectal cancer through involvement of Wnt/β-catenin and COX-2 pathways.

Authors:  Nurul Husna Shafie; Norhaizan Mohd Esa; Hairuszah Ithnin; Abdah Md Akim; Norazalina Saad; Ashok Kumar Pandurangan
Journal:  Biomed Res Int       Date:  2013-10-24       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.